← All organizations
Bridge BioResearch Ltd.
For profitContributed to NME
Also known as: BRIDGEBIO PHARMA INC | Cantero Therapeutics, a BridgeBio company | CoA Therapeutics, Inc., a BridgeBio company | Phoenix Tissue Repair, a BridgeBio company | QED Therapeutics, a BridgeBio company | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics
Highest phase reached
Phase 3
First clinical trial
Jul 1, 2011First marketed drug
Nov 22, 2024First NDA
Nov 22, 2024Last known activity
Nov 30, 2025
Defunct as of Aug 24, 2017
Timeline
2000s
- Jun 1, 2004
Bridge BioResearch Ltd.— Founded
2010s
- Aug 24, 2017
Bridge BioResearch Ltd.— Defunct
2020s
- Nov 22, 2024
Acoramidis— NDA Organization
Drugs by trial phase (14 distinct, 9 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (2 own, 0 via acquisition)
Phase 1 (11 own, 0 via acquisition)
Indications
Studied for
Marketed drugs (1)
Recent trials (9)
- NCT07169279Lead sponsorPhase 2Nov 30, 2025
- NCT06873035Lead sponsorPhase 2/Phase 3May 31, 2025
- NCT06917079Lead sponsorPhase 1Mar 31, 2025
- NCT06625775Lead sponsorPhase 1Oct 29, 2024
- NCT06343402Lead sponsorPhase 1May 22, 2024
- NCT05143190CollaboratorPhase 2Nov 25, 2021
- NCT04876924Lead sponsorPhase 1Apr 29, 2021
- NCT04836494Lead sponsorPhase 1Mar 25, 2021
- NCT01342497Lead sponsorPhase 2Jul 1, 2011
Details
- Founded
- London, GB Jun 1, 2004
- First NDA
- Nov 22, 2024
- Last known activity
- Nov 30, 2025
Designations held
- Orphan drug